1-Deamino-8-d-arginine vasopressin (DDAVP): a potential new treatment for the bleeding diathesis of acute renal failure

Pharmatherapeutica. 1984;3(9):618-22.


The treatment of the haemorrhagic tendency of acute renal failure remains unsatisfactory. To investigate a potential new therapy, 8 patients with acute renal failure and prolonged bleeding times received an infusion of 1-deamino-8-d-arginine vasopressin (0.4 microgram/kg). This resulted in significant shortening of the bleeding time at 1 and 2 hours post-infusion. The beneficial effect on bleeding time had largely disappeared by 8 hours. Pre-infusion Factor VIII activities were either within the normal range or mildly increased and a tendency to further elevation was noted post-DDAVP. In contrast, no alteration in platelet count or haematocrit was observed. No adverse effects were reported, and no significant change in heart rate, blood pressure or plasma osmolarity was noted.

MeSH terms

  • Acute Kidney Injury / complications*
  • Arginine Vasopressin / therapeutic use*
  • Bleeding Time
  • Deamino Arginine Vasopressin / therapeutic use*
  • Factor VII / metabolism
  • Female
  • Hemorrhagic Disorders / drug therapy*
  • Hemorrhagic Disorders / etiology
  • Humans
  • Male
  • Platelet Function Tests
  • Time Factors


  • Arginine Vasopressin
  • Factor VII
  • Deamino Arginine Vasopressin